The joint PDA IPEC risk assessment for excipient technical report has recently been published. The report provides guidance to drug manufacturers on how to tackle the risk assessments for excipients used in finished drugs and provides several examples that can be used by manufacturers in their quality programs. The document also provides a mechanism to review existing programs and fine-tune the risk assessment process to align with industry best practices.
PDA and the IPEC Federation Publish Technical Report No. 54-6: Formalized Risk Assessment for Excipients - Webinar
Cancellation Policy
Note:
Cancellations for live webinars must be made in writing and can be mailed or e-mailed to:
IPEC-Americas Webinars
3138 10th Street N
Arlington, VA 22201
Suite 500
E-mail: ipecamer@ipecamericas.org
Registration fees are refundable for attendees registered for individual webinars, if cancellation is received at least five (5) business days prior to the course. Notices of cancellation received 0-4 business days prior to the course will not be provided a refund. If you registered and are unable to attend the webinar, a recording of the webinar will be provided.
No cancellations are available for webcasts (archived recorded webinars). Recordings are available for 21 days after purchase.
Questions?
Please contact IPEC-Americas Training Coordinator
571-814-3449 or email ipecamer@ipecamericas.org